Skip to main content
生物谷 logo

生物谷 — Investor Relations & Filings

Ticker · 920266 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2022-12-08 Governance Information
Country CN China
Listing Beijing Stock Exchange 920266

About 生物谷

https://www.bioon.com/

Bio-Valley specializes in the research, development, and manufacturing of botanical-based therapeutic solutions, with a primary focus on cardiovascular and cerebrovascular health. The company is a leader in the industrialization of Erigeron breviscapus (Dengzhanhua), a botanical resource used for treating ischemic stroke and its sequelae. Its core product portfolio includes Dengzhan Shengmai Capsules and Dengzhan Xixin Injection, which are utilized in clinical settings for their neuroprotective and microcirculation-improving properties. Bio-Valley maintains a comprehensive value chain encompassing botanical cultivation, standardized extraction, and large-scale production. By leveraging advanced extraction technologies and rigorous quality control, the company provides evidence-based solutions for chronic disease management and geriatric care.

Recent filings

Filing Released Lang Actions
董事会薪酬与考核委员会工作细则
Governance Information Classification · 95% confidence The document is titled as the 'Work Rules of the Board Remuneration and Assessment Committee' of Yunnan Biological Valley Pharmaceutical Co., Ltd. It details the committee's composition, responsibilities, decision-making procedures, and meeting rules. It is a governance-related document focusing on internal board committee rules and procedures, not a financial report or announcement of voting results. There is no indication of financial data, voting results, or report publication. The content aligns with governance information about board structure and practices.
2022-12-08 Chinese
关联交易公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a related party transaction involving the leasing of office space between the company and its controlling shareholder. It details the transaction terms, pricing policy, approvals by the board and supervisory committee, and the impact on the company. There is no financial statement or comprehensive financial report included. The document is a regulatory announcement about a related party transaction, which fits best under the category of Regulatory Filings (RNS) as it does not match other more specific categories like Annual Report, Interim Report, or Capital/Financing Update. The document length is 3409 characters, which is typical for an announcement rather than a full report.
2022-12-08 Chinese
联席董事长任命公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the appointment of a co-chairman of the board of directors at Yunnan Shengwu Gu Pharmaceutical Co., Ltd. It details the election results, the appointee's qualifications, and the impact of the appointment on the company. There is no financial data, no mention of financial results, reports, or regulatory filings beyond the appointment. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2022-12-08 Chinese
董事会审计委员会工作细则
Governance Information Classification · 95% confidence The document is titled '云南生物谷药业股份有限公司 董事会审计委员会工作细则' which translates to 'Yunnan Biovalley Pharmaceutical Co., Ltd. Board Audit Committee Working Rules'. It details the structure, responsibilities, composition, and procedures of the audit committee of the board of directors. It is a governance-related document describing internal rules and committee functions rather than financial results, audit opinions, or announcements of voting results. The document is not an audit report, annual report, or any financial statement. It is not a regulatory filing or announcement but a governance framework document. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 3033 characters, which is sufficient for a detailed governance report rather than a brief announcement.
2022-12-08 Chinese
董事、监事薪酬管理制度
Remuneration Information Classification · 95% confidence The document is titled '云南生物谷药业股份有限公司 董事、监事薪酬管理制度' which translates to 'Yunnan Biological Valley Pharmaceutical Co., Ltd. Directors and Supervisors Remuneration Management System'. It details the remuneration policies, principles, management structure, salary standards, payment, and adjustment mechanisms for the company's board members and supervisors. It includes procedural and governance aspects related to compensation but does not contain financial statements or earnings data. The document is a formal policy or governance document related to remuneration, not a report of financial results or an announcement of voting results. It is not a proxy solicitation or remuneration disclosure report but a remuneration management system document. Therefore, it fits best under the category of Remuneration Information (DEF 14A), which covers reports detailing compensation for top executives and directors. The document length is 3106 characters, which is consistent with a detailed policy document rather than a brief announcement or a full annual report. Hence, the classification is DEF 14A with high confidence.
2022-12-08 Chinese
独立董事关于第四届董事会第十二次会议相关事项的独立意见公告
Board/Management Information Classification · 95% confidence The document is an announcement from independent directors providing their opinions on specific board meeting matters, including approval of related party transactions and write-off of receivables. It references the fourth board meeting of the fourth session held on December 8, 2022. The content focuses on independent directors' opinions regarding board resolutions rather than financial results or management reports. It does not contain financial statements or detailed financial analysis. The document is a formal announcement related to board/management matters, specifically independent directors' opinions on board meeting agenda items. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not a report or a certification, so it is not RNS or RPA.
2022-12-08 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.